about
The autoimmune disease-associated transcription factors EOMES and TBX21 are dysregulated in multiple sclerosis and define a molecular subtype of diseaseCountry, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndromeThe Australian Multiple Sclerosis (MS) immunotherapy study: a prospective, multicentre study of drug utilisation using the MSBase platformA new era in the treatment of multiple sclerosisGenome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci.Muscle-specific kinase antibody positive myaesthenia gravis and multiple sclerosis co-presentation: a case report and literature review.Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association oData quality evaluation for observational multiple sclerosis registries.Geographical variations in sex ratio trends over time in multiple sclerosis.Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosisGenetic variants are major determinants of CSF antibody levels in multiple sclerosis.Predictors of disability worsening in clinically isolated syndrome.Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MSAnalysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies. MS Neurology Group of the Australian and New Zealand Association of NeuroloTherapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 3 treatment practicalities and recommendations. MS Neurology Group of the Australian and New Zealand Association ofIncreasing age at disability milestones among MS patients in the MSBase Registry.Defining secondary progressive multiple sclerosis.Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis.CSF hypotension: A review of its manifestations, investigation and management.Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis.Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study.Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study.Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis.Incidence and prevalence of NMOSD in Australia and New Zealand.The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.Contribution of different relapse phenotypes to disability in multiple sclerosis.Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis.A case of valproate induced hyperammonemic encephalopathy.Parkinsonism and dementia due to gliomatosis cerebri mimicking sporadic Creutzfeldt-Jakob disease (CJD).Relapsing encephalopathy with headache: an unusual presentation of isolated intracranial neurosarcoidosis.Ribosomal protein S6 mRNA is a biomarker upregulated in multiple sclerosis, downregulated by interferon treatment, and affected by season.Speech-activated myoclonus: an uncommon form of action myoclonus.Late effects of oxaliplatin-induced peripheral neuropathy (LEON)--cross-sectional cohort study of patients with colorectal cancer surviving at least 2 years.Predictors and dynamics of postpartum relapses in women with multiple sclerosis.Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis.Sex as a determinant of relapse incidence and progressive course of multiple sclerosis.Seasonal variation of relapse rate in multiple sclerosis is latitude dependent.
P50
Q28307281-3B1F3DE4-4D8B-48B4-B326-B68C4F323AD1Q28480907-12832884-28E1-47EB-88AB-646869073609Q28488248-FDB5694E-2CDF-49D2-A698-9178BBB1631CQ29395420-FAB177F0-9D63-45EE-851A-01AE28E7F304Q29417047-728F3D56-58A7-477A-A533-74C909CC69CAQ30667287-97E08354-7E45-40BA-81DE-AA15EE230542Q30834551-F1334DCF-29AF-42DD-8899-1D25E66C5977Q31119031-5D922296-487C-450D-A97A-CFE4C3CFDE7CQ34469310-97955A50-A3C5-47D8-84D5-8752BC292D15Q34737478-C63B46C0-7F89-412B-A796-61D127DC32F1Q35533986-94A66683-C763-42E0-B5A3-B964888E4E69Q35619185-17A8422E-F0B2-437E-ADF5-3B61D699EEF3Q35653675-7F2B8BC0-7A74-4256-A293-CD9FCD289B82Q37322100-480A0FE8-3FFC-491E-B901-33003101E0D6Q38226014-AEA08ED9-E5F8-4D81-BC65-DAA61E5E282CQ38226016-F37D6864-BA11-4741-9DB0-BFC03DDFA9FAQ38433183-454A49AF-2127-4EB9-BB7B-73F52F0056BEQ38843046-BE8AA5E5-DD2A-4F45-9994-4D4EDC2D8204Q38850911-4401BA50-95A3-465F-A014-89FF56C66836Q38921175-4D9C9317-CC0F-4DD3-B63A-5C9B991DD7D9Q38956663-0D564DBD-F902-462E-BF66-F4894F835AD8Q39139645-C0AFE574-FF19-4109-96FA-0D9F05CE5ED7Q39685700-008B31A2-64E1-4F7D-B7F8-DD34563B7DEFQ39900185-B10ACD4E-0BFB-46D0-AB14-176465D5D8C4Q40073097-E0162049-295A-43E1-852A-C7FA484F7409Q40183457-31CD70E6-42BD-4CB7-9286-8FD98761D26DQ40710140-81BF3D84-F208-4918-94B6-9C96C021842DQ40724148-D4FD839F-83EB-4622-95AF-E82FE9A8B83FQ41721827-9834AE7C-1B88-447F-AE7F-E292CCFB599CQ42187061-6959EDC1-15A1-4F20-ABD0-2B74AA218B75Q42718515-DC31BBE7-A2DD-47F2-8F2B-D07CB7B851C4Q42765744-DD9BD2B1-F915-4C67-A18B-296CE8F5A76CQ42774255-ED3EDE54-389C-4CCC-8CCE-0615C8382A83Q44767761-2BCFBC8A-BF72-47D2-B986-5B9D5CAC0EB3Q45719835-0784FE07-E6A9-4834-A907-8F8DF39BEFA4Q45832934-6BBB5183-52AF-4A08-B4FF-82A15D43D6F8Q47639943-B21AC543-5735-474C-89A9-CB0ADE14CDD4Q48329925-54E59A79-B18C-4780-841F-9D53B2A4FCFBQ48922719-AC248E3A-C63A-4817-AE19-ACFF61E535C7Q51260423-09D961A2-2CAF-4611-B6C2-96B1E627169E
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Mark Slee
@ast
Mark Slee
@en
Mark Slee
@es
Mark Slee
@sl
type
label
Mark Slee
@ast
Mark Slee
@en
Mark Slee
@es
Mark Slee
@sl
prefLabel
Mark Slee
@ast
Mark Slee
@en
Mark Slee
@es
Mark Slee
@sl
P1053
J-4731-2015
P106
P21
P31
P3417
Mark-Slee-1
P3829
P496
0000-0003-4323-2453